Free Trial

Beyond Air Q3 2025 Earnings Report

Beyond Air logo
$0.35 -0.01 (-1.49%)
As of 02/21/2025 04:00 PM Eastern

Beyond Air EPS Results

Actual EPS
-$0.15
Consensus EPS
-$0.24
Beat/Miss
Beat by +$0.09
One Year Ago EPS
-$0.50

Beyond Air Revenue Results

Actual Revenue
N/A
Expected Revenue
$0.93 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Beyond Air Announcement Details

Quarter
Q3 2025
Time
After Market Closes

Beyond Air Earnings Headlines

Head to Head Contrast: Penumbra (NYSE:PEN) versus Beyond Air (NASDAQ:XAIR)
9/9 on TSLA from June to January
Please take a look at THIS case study on Target (TGT) You’ll see exactly how the tool works to trade long and short, even when the markets seem to be predicting the exact opposite. Now, this tool has been so accurate over recent months that I’m planning to send you 14 more real-world examples of winning trades that anyone using this tool could have captured. And it’s all building to Monday, February 24 @ 1pm ET when I’ll bring the tool to the public for the first time and show you how you can put it on your own charts!
Roth Capital Brokers Boost Earnings Estimates for Beyond Air
Roth Capital Comments on Beyond Air FY2029 Earnings
See More Beyond Air Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Beyond Air? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Beyond Air and other key companies, straight to your email.

About Beyond Air

Beyond Air (NASDAQ:XAIR) operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.

View Beyond Air Profile

More Earnings Resources from MarketBeat